EUVIMEDEUVIMED entdecken
Crossref

HBsAg Quantification‐Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs‐Experienced Patients With Chronic Hepatitis B: The HBsAg ‐ HCC Score

Yi-Fan Guo, Xiao-Xia Niu, Le Li, Yan Chen, Yan Liu iD, Chang Guo, Meng-Qi Sun, Yi-Zhe Zhang, Xu-Yang Li iD, Chun-Yan Wang, Jian-Jun Wang, Lin Tan und 2 weitere

Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (1) · 62-73

DOI: 10.1111/apt.70652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 03.04.2026. Verfasst von Yi-Fan Guo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Hepatology, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Hepatitis B Surface Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, National Major Science and Technology Projects of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic hepatitis B (CHB) virus infection is the leading cause of hepatocellular carcinoma (HCC). Nucleos(t)ide analogs (NAs) effectively suppress HBV replication, but residual HCC risk remains in treated patients, highlighting the need for reliable risk stratification tools. Existing prediction models rely heavily on age and liver function parameters and often overlook hepatitis B surface antigen (HBsAg) quantification, a key marker closely tied to HBV‐related HCC, resulting in inadequate clinical predictive accuracy.

Methods

To address this gap, we developed the novel HBsAg‐HCC Score using a two‐cohort design: retrospective training (1190 NA‐treated CHB patients) with Cox regression to identify independent HCC risk factors, followed by validation in an independent prospective cohort (506 patients). Its performance was compared with three established tools (PAGE‐B, mPAGE‐B, aMAP).

Results

Five independent HCC risk factors were identified: higher HBsAg levels, older age, male sex, hypoproteinaemia, and elevated APRI. The HBsAg‐HCC Score derived from these factors showed strong predictive power: 3‐/5‐/7‐year AUCs of 0.867/0.872/0.871 in the training cohort (significantly outperforming PAGE‐B, mPAGE‐B, aMAP) and 0.784/0.780/0.777 in the validation cohort. Internal and external cross‐validation confirmed its stability and reliability.

Conclusions

By incorporating HBsAg quantification, a virus‐specific marker often missing from conventional models, the HBsAg‐HCC Score offers a more comprehensive and accurate approach to HCC risk stratification in NAs‐experienced CHB patients, addressing a critical limitation of existing models directly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsHepatitis B Surface AntigensAntiviral AgentsNucleosidesHumansFemaleMaleRisk FactorsMiddle AgedRetrospective StudiesAdultPredictive Value of TestsRisk Assessment

Stichwörter der Autor:innen

HBsAgantiviral treatmentchronic hepatitis Bhepatocellular carcinomarisk prediction

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsNucleosides

Autor:innen und Institutionen

  • Senior Department of Hepatology, Chinese PLA General Hospital, Beijing, China.
  • Peking University 302 Clinical Medical School, Beijing, China.
  • Senior Department of Infectious Diseases, Chinese PLA General Hospital, Beijing, China.
  • Department of Outpatient, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Chinese PLA Medical School, Beijing, China.
  • Department of Liver Disease, The Second People's Hospital of Fuyang City, Anhui, China.

ORCID-Profile: Yan Liu, Xu-Yang Li, Dong Ji

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • National Major Science and Technology Projects of China

Zitieren

APA

Guo, Y. F., Niu, X. X., Li, L., Chen, Y., Liu, Y., Guo, C., Sun, M. Q., Zhang, Y. Z., Li, X. Y., Wang, C. Y., Wang, J. J., Tan, L., Lau, G., & Ji, D. (2026). HBsAg Quantification‐Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs‐Experienced Patients With Chronic Hepatitis B: The HBsAg ‐ HCC Score. Alimentary Pharmacology & Therapeutics, 64(1), 62-73. https://doi.org/10.1111/apt.70652

Vancouver

Guo YF, Niu XX, Li L, Chen Y, Liu Y, Guo C, et al. HBsAg Quantification‐Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs‐Experienced Patients With Chronic Hepatitis B: The HBsAg ‐ HCC Score. Alimentary Pharmacology & Therapeutics. 2026;64(1):62-73. doi:10.1111/apt.70652

BibTeX
@article{Guo2026,
  author = {Guo, Yi-Fan and Niu, Xiao-Xia and Li, Le and Chen, Yan and Liu, Yan and Guo, Chang and Sun, Meng-Qi and Zhang, Yi-Zhe and Li, Xu-Yang and Wang, Chun-Yan and Wang, Jian-Jun and Tan, Lin and Lau, George and Ji, Dong},
  title = {HBsAg Quantification‐Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs‐Experienced Patients With Chronic Hepatitis B: The HBsAg ‐ HCC Score},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {1},
  pages = {62--73},
  doi = {10.1111/apt.70652}
}
Kostenlos starten →